THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 11, 2005--Amgen Inc.
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced a significant increase in its funding to
foundation-sponsored patient assistance programs for 2005. These
programs are designed to ensure access for patients with cancer or
kidney disease who cannot afford the co-payments for prescription drug
therapies critical to their overall treatment. Amgen is increasing the
level of this patient assistance to an unprecedented $18 million in
"Ensuring that patients have access to innovative therapies is
part of Amgen´s commitment to helping patients facing serious illness
live better and longer lives," said George Morrow, executive vice
president, global commercial operations at Amgen.
With the $18 million, Amgen is providing grants to several
independent non-profit charitable foundations to assist patients in
2005. Each foundation will assess patients´ eligibility to receive
co-payment assistance based upon their own independent objective
Providers and patients interested in determining what financial
assistance programs may be available should call Amgen´s Reimbursement
Connection(R) at 1-800-272-9376. The Reimbursement Connection has an
extensive database of potential resources available to assist patients
who are uninsured, underinsured or need assistance in paying their
co-pays, including referral to independent patient assistance
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
EDITOR´S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Andrea Rothschild, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)